Cargando…

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation

Detalles Bibliográficos
Autores principales:	Zhao, Xue-Song, Zhou, Jing, Dong, Lei, Zhang, Hui, Ye, Ying-Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964940/ https://www.ncbi.nlm.nih.gov/pubmed/31764178 http://dx.doi.org/10.1097/CM9.0000000000000550

Ejemplares similares

ARID1A: guardian of normal pancreatic ducts
por: Castellanos, Karla J., et al.
Publicado: (2019)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Male Paraurethral Duct Infection and Subsequent Paraurethral Duct Dilation
por: Fan, Wen-Ge, et al.
Publicado: (2015)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
por: Lundy, Joanne, et al.
Publicado: (2022)

Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report
por: Lai, Yi-Hsuan, et al.
Publicado: (2022)

Protein Plug in the Pancreatic Duct Mimicking Pancreatic Adenocarcinoma
por: Yamaguchi, Takeru, et al.
Publicado: (2019)

Laparoscopic transcystic common bile duct exploration and laparoscopic transductal common bile duct exploration in elderly patients with cholecystolithiasis combined with choledocholithiasis
por: Wang, Yun-Feng, et al.
Publicado: (2019)

Is there any role of staging laparoscopy in pancreatic adenocarcinoma?
por: Soni, Theresa, et al.
Publicado: (2023)

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
por: Valiakhmetova, Andge, et al.
Publicado: (2019)

A commentary on ‘Does pancreatic duct stent placement lead to decreased postoperative pancreatic fistula rates after pancreaticoduodenectomy? A meta-analysis’
por: Tang, Chengwu, et al.
Publicado: (2023)

Deleterious effects of catecholamine administration in acute heart failure caused by unrecognized Takotsubo cardiomyopathy
por: Dandel, Michael, et al.
Publicado: (2018)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma
por: Wang, Lei-Ming, et al.
Publicado: (2021)

Lung adenocarcinoma associated with cystic airspaces
por: Yang, Xue, et al.
Publicado: (2022)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma
por: Chen, Jianing, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Nasopalatine duct cyst – Diagnosis from the content in the cystic wall
por: Chen, I-Jen, et al.
Publicado: (2023)

Increased Telomerase Activities in Human Pancreatic Duct Adenocarcinomas
por: Tsutsumi, Masahiro, et al.
Publicado: (1997)

Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review
por: Pimenta, Jefferson Rios, et al.
Publicado: (2020)

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
por: File, Danielle M., et al.
Publicado: (2020)

Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
por: Zhang, Li, et al.
Publicado: (2021)

Nasopalatine duct cyst – Case report
por: Lang, Ming-Jane, et al.
Publicado: (2021)

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
por: Li, Caixia, et al.
Publicado: (2022)

Development and validation of m6A RNA methylation regulators-based signature in lung adenocarcinoma
por: Guo, Wei, et al.
Publicado: (2021)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Antibody durability at 1 year after Sputnik V vaccination
por: Sanchez, Lautaro, et al.
Publicado: (2022)

A Conjunctival Melanoma with Invasion of the Nasolacrimal Duct
por: Matsunaga, Takuma, et al.
Publicado: (2022)

Coexistent Ampullary Squamous Cell Carcinoma with Adenocarcinoma of the Pancreatic Duct
por: Pathak, Gayatri S., et al.
Publicado: (2011)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency
por: Pang, Xionghao, et al.
Publicado: (2020)

Nasolacrimal Duct Stenosis after Oral Capecitabine Administration
por: Jang, Yeonji, et al.
Publicado: (2019)

Deleterious GRM1 Mutations in Schizophrenia
por: Ayoub, Mohammed Akli, et al.
Publicado: (2012)

Validation of Deleterious Mutations in Vorderwald Cattle
por: Reinartz, Sina, et al.
Publicado: (2016)

The Pattern and Distribution of Deleterious Mutations in Maize
por: Mezmouk, Sofiane, et al.
Publicado: (2013)

Origin and Evolution of Deleterious Mutations in Horses
por: Orlando, Ludovic, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cdcu1q1nr8qa3a8744tdjib3rc